Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm's price target on Adaptive Biotechnologies to $20 from $18 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.